Results 61 to 70 of about 2,468,898 (371)
Soluble VEGFR‐2: an antilymphangiogenic variant of VEGF receptors
Annals of the New York Academy of Sciences, 2010 The vascular endothelial growth factor (VEGF) family of secreted proteins and their receptors are major regulators of blood vessel development (hemangiogenesis) and lymphatic vessel development (lymphangiogenesis).
H. Pavlaković +4 more
semanticscholar +1 more source
Proceedings of the National Academy of Sciences of the United States of America, 2006 Recent evidence indicates a specific role for vascular endothelial growth factor a (Vegfa) during artery development in both zebrafish and mouse embryos, whereas less is known about signals that govern vein formation.
Laurence D. Covassin +4 more
semanticscholar +1 more source
Frontiers in Oncology, 2013 Angiogenesis, the formation of new blood vessels from existing vasculature, is important in tumor growth and metastasis. A key regulator of angiogenesis is vascular endothelial growth factor (VEGF), which has been targeted in numerous anti-angiogenic ...
Stacey D Finley +2 more
doaj +1 more source
Peculiarities of serum levels of vascular growth factor and its receptors in dialysis patients
Український Журнал Нефрології та Діалізу, 2022 Recent research has shown that VEGF may influence the condition and survival of patients with chronic kidney disease (CKD), including those treated with dialysis procedures.
V. Driianska +5 more
doaj +1 more source
Algebraic study of receptor-ligand systems: a dose-response analysis [PDF]
arXiv, 2022 The study of a receptor-ligand system generally relies on the analysis of its dose-response (or concentration-effect) curve, which quantifies the relation between ligand concentration and the biological effect (or cellular response) induced when binding its specific cell surface receptor.
arxiv
Journal of Biological Chemistry, 1996 Vascular endothelial growth factor (VEGF), a potent angiogenic factor, uses two receptor tyrosine kinases, FLK/KDR and FLT, to mediate its activities. We have cross-linked I-VEGF to the cell surface of various tumor cell lines and of human umbilical vein
S. Soker +3 more
semanticscholar +1 more source
Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells
Molecular Oncology, EarlyView.In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi +3 more
wiley +1 more source
Journal of Translational Medicine, 2023 Abstract Background CD4+ cytotoxic T cells (CD4 CTLs) are CD4+ T cells with major histocompatibility complex-II-restricted cytotoxic function. Under pathologic conditions, CD4 CTLs hasten the development of autoimmune disease or viral infection by enhancing cytotoxicity. However, the regulators of the cytotoxicity of CD4
Ziyi Chen +9 more
openaire +3 more sources
Molecular Oncology, EarlyView.The authors applied joint/mixed models that predict mortality of trifluridine/tipiracil‐treated metastatic colorectal cancer patients based on circulating tumor DNA (ctDNA) trajectories. Patients at high risk of death could be spared aggressive therapy with the prospect of a higher quality of life in their remaining lifetime, whereas patients with a ...
Matthias Unseld +7 more
wiley +1 more source
VEGF-A, VEGF-C, and VEGF-D in Colorectal Cancer Progression
Neoplasia: An International Journal for Oncology Research, 2001 We aimed to assess the relationship of the angiogenic cytokines VEGF-A, VEGF-C, and VEGF-D and their receptors VEGFR-2 and VEGFR-3 in the adenomacarcinoma sequence and in metastatic spread of colorectal cancer (CRC).
Mark L. George +6 more
doaj +1 more source